NCT07623577 Sac-TMT Combined With Bevacizumab in TNBC With Brain Metastases Status RECRUITING Phase PHASE2
NCT07622836 A Prospective, Multicenter, Phase II Clinical Study of Postoperative Chemotherapy Combined With QL1706 for High-risk Triple-negative Breast Cancer. Status RECRUITING Phase NA
NCT07552181 Phase II Trial of Pembrolizumab/Chemotherapy With Live Biotherapeutic Product MO-03 in Patients With Early Stage Triple Negative Breast Cancer Status NOT_YET_RECRUITING Phase PHASE2
NCT07536815 An Open-Label, Multicenter, Non-Randomized Expanded Access Protocol (EAP) Designed to Provide Leronlimab to Patients With Locally Advanced or Metastatic Triple-Negative Breast Cancer (mTNBC) Status AVAILABLE Phase N/A
NCT07491822 A Single-Arm, Single-Center, Phase II Clinical Study of Camrelizumab Combined With Radiochemotherapy as Neoadjuvant Therapy for Early-Stage Triple-Negative Breast Cancer Status NOT_YET_RECRUITING Phase NA
NCT07441512 A Phase II, Single-arm Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Eribulin in Pretreated Advanced Triple-negative Breast Cancer Harboring a PIK3CA Mutation Status NOT_YET_RECRUITING Phase PHASE2
NCT07376629 A Study of HB0025 Plus Nab-paclitaxel as First Line Therapy for TNBC Status ENROLLING_BY_INVITATION Phase PHASE2
NCT07021261 Comparing UTD2 Combined With Capecitabine to Capecitabine as Adjuvant Therapy for Non-pCR TNBC Patients Status NOT_YET_RECRUITING Phase PHASE3
NCT07017673 Phase II Trial of Ivonescimab in Combination With Carboplatin + Docetaxel in Patients With Early-Stage Triple Negative Breast Cancer Status RECRUITING Phase PHASE2
NCT06991790 Sacituzumab Govitecan + Toripalimab as First - Line Therapy for Advanced Triple - Negative Breast Cancer and Biomarker Exploration Status RECRUITING Phase N/A
NCT06769425 HS-10502 Combination Treatment in Patients With Advanced Solid Tumors Status RECRUITING Phase PHASE1
NCT06746870 A Phase II Clinical Study to Evaluate the Safety, Pharmacokinetic Profile, and Preliminary Efficacy of IMM2510 in Combination with Chemotherapy As First-line Treatment in Subjects with Non-small Cell Lung Cancer or Triple-negative Breast Cancer Status NOT_YET_RECRUITING Phase PHASE2
NCT06682793 A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression Status RECRUITING Phase PHASE1/PHASE2
NCT06210438 SHR-A1921 Combined With Bevacizumab in Triple-negative Breast Cancer With Brain Metastases Status NOT_YET_RECRUITING Phase PHASE2
NCT05918133 A Study of PM8002 Plus Nab-paclitaxel as First Line Therapy for TNBC Status ACTIVE_NOT_RECRUITING Phase PHASE1/PHASE2
NCT05581004 A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors Status ACTIVE_NOT_RECRUITING Phase PHASE1
NCT04585750 The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) Status RECRUITING Phase PHASE1/PHASE2